Idarucizumab for Dabigatran Reversal

New England Journal of Medicine - Tập 373 Số 6 - Trang 511-520 - 2015
Charles V. Pollack, Paul Reilly1, John W. Eikelboom2, Stephan Glund3, Peter Verhamme4, Richard A. Bernstein5, Robert Dubiel1, Menno V. Huisman6, Elaine M. Hylek7, Pieter W. Kamphuisen8, Jörg Kreuzer9, Jerrold H. Levy10, Frank W. Sellke11, Joachim Stangier3, Thorsten Steiner12, Bushi Wang1, Chak‐Wah Kam13, Jeffrey I. Weitz2,14
1Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT
2McMaster University
3Boehringer Ingelheim Pharma, Biberach
4University of Leuven, Leuven, Belgium
5Northwestern University, Chicago
6Leiden University Medical Center, Leiden
7Boston University School of Medicine, Boston
8University Medical Center Groningen, Groningen
9Ingelheim
10Duke University Medical Center, Durham, NC
11Brown Medical School and Rhode Island Hospital, Providence, RI
12Klinikum Frankfurt Höchst, Frankfurt am Main, and Heidelberg University Hospital, Heidelberg
13Tuen Mun Hospital, Tuen Mun, NT, Hong Kong
14Thrombosis and Atherosclerosis Research Institute

Tóm tắt

Từ khóa


Tài liệu tham khảo

10.1056/NEJMoa0905561

10.1182/blood-2014-03-563056

10.1161/CIRCULATIONAHA.114.012061

10.1160/TH09-11-0758

10.1182/blood-2012-11-468207

10.1160/TH14-12-1080

10.1182/blood-2014-02-514778

Glund S, 2015, Lancet

10.1016/j.jacc.2013.07.104

10.1111/j.1538-7836.2009.03678.x

10.1056/NEJM199309023291001

10.1161/01.STR.0000027437.22450.BD

10.1161/STROKEAHA.111.639708

Sarode R, 2013, Circulation, 128, 1234, 10.1161/CIRCULATIONAHA.113.002283

Thông tin
Thông tin xuất bản

New England Journal of Medicine

Tập 373 Số 6

511-520

Thông tin tác giả